Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Oak Bay Partners
Victoria, British Columbia, Canadavancouverislandfreedaily.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Oak Bay Biosciences is developing a preclinical therapy for Stargardt disease using an optimized nucleic acid aptamer that inhibits complement factor D. The company has established a team of experts and key scientific collaborations to complete its preclinical data package ahead of anticipated clinical trials. No clinical results are available yet as the program is in preclinical development[6].
- Therapeutic areas
- Ophthalmology
- Modalities
- Nucleic acid aptamerSynthetic oligonucleotide
- Industry
- Biotech
02
Partnerships
No major pharmaceutical or biotech partnerships disclosed as of the latest information.
Beyond the preview
Go deeper on Oak Bay Partners.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oak Bay Partners.